Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver
Xiaohan Xu1; Kyle L. Poulsen2; Lijuan Wu1; Shan Liu3; Tatsunori Miyata4; Qiaoling Song3; Qingda Wei5; Chenyang Zhao1; Chunhua Lin6; Jinbo Yang1
发表期刊Signal Transduction and Targeted Therapy
ISSN2059-3635
卷号7期号:1
英文摘要Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive and more susceptible to developing cirrhosis and hepatocellular carcinoma. Currently, lifestyle interventions are the most essential and effective strategies for preventing and controlling NAFL without the development of fibrosis. While there are still limited appropriate drugs specifically to treat NAFL/NASH, growing progress is being seen in elucidating the pathogenesis and identifying therapeutic targets. In this review, we discussed recent developments in etiology and prospective therapeutic targets, as well as pharmacological candidates in pre/clinical trials and patents, with a focus on diabetes, hepatic lipid metabolism, inflammation, and fibrosis. Importantly, growing evidence elucidates that the disruption of the gut–liver axis and microbe-derived metabolites drive the pathogenesis of NAFL/NASH. Extracellular vesicles (EVs) act as a signaling mediator, resulting in lipid accumulation, macrophage and hepatic stellate cell activation, further promoting inflammation and liver fibrosis progression during the development of NAFL/NASH. Targeting gut microbiota or EVs may serve as new strategies for the treatment of NAFL/NASH. Finally, other mechanisms, such as cell therapy and genetic approaches, also have enormous therapeutic potential. Incorporating drugs with different mechanisms and personalized medicine may improve the efficacy to better benefit patients with NAFL/NASH.
语种英语
文献类型期刊论文
条目标识符http://ir.yic.ac.cn/handle/133337/32023
专题中国科学院烟台海岸带研究所知识产出
作者单位1.中国海洋大学
2.University of Texas Health Science Center
3.黑龙江省环境保护科学研究院
4.熊本大学
5.郑州大学
6.中国科学院烟台海岸带研究所
推荐引用方式
GB/T 7714
Xiaohan Xu,Kyle L. Poulsen,Lijuan Wu,et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver[J]. Signal Transduction and Targeted Therapy,7(1).
APA Xiaohan Xu.,Kyle L. Poulsen.,Lijuan Wu.,Shan Liu.,Tatsunori Miyata.,...&Jinbo Yang.
MLA Xiaohan Xu,et al."Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver".Signal Transduction and Targeted Therapy 7.1
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xiaohan Xu]的文章
[Kyle L. Poulsen]的文章
[Lijuan Wu]的文章
百度学术
百度学术中相似的文章
[Xiaohan Xu]的文章
[Kyle L. Poulsen]的文章
[Lijuan Wu]的文章
必应学术
必应学术中相似的文章
[Xiaohan Xu]的文章
[Kyle L. Poulsen]的文章
[Lijuan Wu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。